Human Placenta Extract in Aesthetic Medicine: What Practitioners Should Know

Alongside more familiar tools such as dermal fillers, neuromodulators and chemical peels, some clinics also work with human placenta extract (HPE) — an ingredient used in select topical and injectable skin-quality products, with a longer history of use in parts of Asia and Europe than in some other markets. It remains less widely known, and in certain jurisdictions its use is limited by regulatory restrictions. This overview is educational and is not a recommendation for a specific treatment pathway.

What Human Placenta Extract Is

HPE is derived from full-term human placenta collected after delivery, then purified and processed under sterilisation protocols before use in medical or cosmetic products. It has a long history in East Asian medicine and has been studied for anti-inflammatory, antioxidant and tissue-repair properties, generally attributed to the placenta's biological role during pregnancy as a nutrient-transfer and protective filter between mother and foetus.

A Longer History Than It Might Appear

Interest in placental tissue as a therapeutic material predates its current cosmetic applications by decades. In the mid-twentieth century, placental suspensions and extracts were used clinically to support the healing of wounds, burns and surgical adhesions, developing out of broader cell-therapy research in ophthalmology. That early clinical work laid the groundwork for the more targeted cosmetic and dermatological applications now associated with HPE, and it is part of why the ingredient carries a longer track record in some regions than newer biotech-derived actives.

Why It Is Associated With Skin Renewal

HPE contains a complex mix of amino acids, proteins, cytokines and growth factors, along with collagen-derived peptides and antioxidant compounds such as phenylalanine, tryptophan and tyrosine. Growth factors work by binding to receptors on the cell surface and influencing cell division, which is the proposed mechanism behind claims linking HPE to epidermal renewal and collagen support. This mode of action places it conceptually alongside other skin-quality injectables, even though its composition differs from HA-based products.

Where the Research Stands

Most published investigation into HPE has come from South Korean and Japanese research groups. Animal studies have suggested a protective effect against oxidative stress and inflammation, and small human studies have looked at symptom relief in areas such as fatigue and menopause-related complaints. Other research has examined applications as varied as cartilage support and hair-related concerns. The evidence base is narrower than for well-established HA injectables, and practitioners should treat claims accordingly — as an area of continued interest rather than a settled clinical consensus. In some East Asian markets, HPE-based products hold specific regulatory approval for defined medical indications, including chronic liver disease support; that is a different regulatory pathway from the cosmetic and skin-quality applications discussed here and should not be conflated with them.

Forms Available in Professional Practice

HPE-based products exist as topical formulations — creams, masks and cleansing bars — as well as injectable and oral supplement forms. Regulatory status varies considerably by country, and practitioners should confirm what is legally available and permitted for use in their own jurisdiction before considering any placenta-derived product, since approval and classification differ significantly from market to market. Injectable forms in particular are subject to the widest variation in regulatory status worldwide, and a product available as a prescription-only medical treatment in one country may be entirely unavailable, or available only as a cosmetic-grade topical, in another.

Sourcing and Safety Considerations

Because HPE is a biological, donor-derived material, sourcing matters more here than for synthetic ingredients. Reputable manufacturers document rigorous screening for viral and other pathogens as part of production, alongside defined sterilisation standards. Practitioners considering HPE-based products, whether topical or injectable, should confirm this documentation is available and treat traceability as a baseline requirement rather than an optional extra. At minimum, clinics should expect to see donor screening protocols, batch-level pathogen testing, and a clearly documented sterilisation method; a supplier unable to provide this on request is not a suitable source for a biologically derived product, regardless of how established the brand appears.

The Takeaway

Human placenta extract occupies a specialised, well-established-in-some-markets corner of the skin-quality ingredient landscape. Its proposed benefits rest on a plausible growth-factor mechanism and a body of research that, while smaller than for mainstream HA injectables, is not negligible — practitioners evaluating it should weigh the evidence, confirm local regulatory status, and prioritise documented sourcing above all else.

Clinics reviewing skin-quality options can browse products such as Curacen alongside other injectables on the skinboosters catalogue.